Are Raf dimers targets for therapeutic intervention in RASopathies?
Awardee: Philip Stork
Institution: Oregon Health & Sciences University
Award Amount: $44,000
Funding Period: January 1, 2017 - December 31, 2017
Previous
Previous
Pharmacological rescue and screening in a Pitt Hopkins model.
Next
Next